Maze Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows company governance is working and shareholders support company decisions by voting.
Leadership changes can affect how well a company runs its finances and operations.
Quarterly earnings reports show if a company is making progress toward profitability.
New money helps companies fund research and operations, but dilutes existing shareholders.
New money helps companies fund research and operations, but dilutes existing shareholders.
Annual reports show total yearly performance and help investors understand company health.
Stocky reads Maze Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Maze Therapeutics, Inc.'s most recent tracked filing was a 8-K on 10 Jun 2026: Stockholders approve 2026 annual meeting matters.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.